Last edition
News about "Agni-01 Clinical Trial"
Obsidian Enrols First Patient in Pivotal-Pathway Study of Engineered TIL Therapy
The phase 1/2 Agni-01 cohort will evaluate amsoki-cel in ICI-resistant advanced melanoma, with enrollment expected to conclude by Q1 2027 and topline data anticipated by year-end 2027.<br />
Agni-01 Clinical Trial | 10/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members